Matrix metalloproteinases. Novel targets for directed cancer therapy
- PMID: 9303281
- DOI: 10.2165/00002512-199711030-00006
Matrix metalloproteinases. Novel targets for directed cancer therapy
Abstract
Matrix metalloproteinases (MMPs), or matrixins, are a family of zinc endopeptidases that play a key role in both physiological and pathological tissue degradation. Normally, there is a careful balance between cell division, matrix synthesis and matrix degradation, which is under the control of cytokines, growth factors and cell matrix interactions. The MMPs are involved in remodelling during tissue morphogenesis and wound healing. Under pathological conditions, this balance is altered: in arthritis, there is uncontrolled destruction of cartilage; in cancer, increased matrix turnover is thought to promote tumour cell invasion. The demonstration of a functional role of MMPs in arthritis and tumour metastasis raises the possibility of therapeutic intervention using synthetic MMP inhibitors with appropriate selectivity and pharmacokinetics. As the process of drug discovery focuses on structure-based design, efforts to resolve the 3-dimensional structures of the MMP family have intensified. Several novel MMP inhibitors have been identified and are currently being investigated in clinical trials. The structural information that is rapidly accumulating will be useful in refining the available inhibitors to selectively target specific MMP family members. In this review, we focus on the role of MMPs and their inhibitors in tumour invasion, metastasis and angiogenesis, and examine how MMPs may be targeted to prevent cancer progression.
Similar articles
-
Matrix metalloproteinase inhibitors.Invest New Drugs. 1997;15(1):61-75. doi: 10.1023/a:1005722729132. Invest New Drugs. 1997. PMID: 9195290 Review.
-
Matrix metalloproteinase inhibitors: applications in oncology.Invest New Drugs. 1999;17(4):387-99. doi: 10.1023/a:1006386406584. Invest New Drugs. 1999. PMID: 10759405 Review.
-
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821. Nat Rev Cancer. 2006. PMID: 16498445 Review.
-
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?Pharmacotherapy. 2002 Jun;22(6):705-20. doi: 10.1592/phco.22.9.705.34062. Pharmacotherapy. 2002. PMID: 12066962 Review.
-
Role of matrix metalloproteinases and their inhibitors in pancreatic cancer.Digestion. 1997;58(6):520-8. doi: 10.1159/000201495. Digestion. 1997. PMID: 9438596 Review.
Cited by
-
Genes that regulate metastasis and angiogenesis.J Neurooncol. 2000 Oct-Nov;50(1-2):71-87. doi: 10.1023/a:1006466605356. J Neurooncol. 2000. PMID: 11245283 Review.
-
NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.PLoS One. 2012;7(3):e34283. doi: 10.1371/journal.pone.0034283. Epub 2012 Mar 29. PLoS One. 2012. PMID: 22479587 Free PMC article.
-
Increased methylation variation in epigenetic domains across cancer types.Nat Genet. 2011 Jun 26;43(8):768-75. doi: 10.1038/ng.865. Nat Genet. 2011. PMID: 21706001 Free PMC article.
-
Advances in fluorescent-image guided surgery.Ann Transl Med. 2016 Oct;4(20):392. doi: 10.21037/atm.2016.10.70. Ann Transl Med. 2016. PMID: 27867944 Free PMC article. Review.
-
Proteolysis in colorectal cancer.Mol Pathol. 1999 Jun;52(3):140-5. doi: 10.1136/mp.52.3.140. Mol Pathol. 1999. PMID: 10621835 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials